Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19-Reference-Cited by-同舟云学术

Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19

Published:2020-08-30 Issue:6 Volume:20 Page:e218-e221
ISSN:1470-2118
Container-title:Clinical Medicine
language:en
Short-container-title:Clin Med

Author:

Conzelmann Carina,Müller Janis A,Perkhofer Lukas,Sparrer Konstantin MJ,Zelikin Alexander N,Münch Jan,Kleger Alexander

Publisher

Royal College of Physicians

Subject

General Medicine

Reference43 articles.

1. A rampage through the body

2. Droplets and Aerosols in the Transmission of SARS-CoV-2

3. Beigel JH , Tomashek KM , Dodd LE . Remdesivir for the treatment of Covid-19 - Preliminary Report. N Engl J Med 2020, in press (doi: 10.1056/NEJMoa2007764).

4. Drug repurposing: progress, challenges and recommendations

5. Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nebulized enriched heparin improves respiratory parameters in patients with COVID-19: a phase I/II randomized and triple-blind clinical trial;Scientific Reports;2024-08-27

2. A review on multifaceted biomedical applications of heparin nanocomposites: Progress and prospects;International Journal of Biological Macromolecules;2024-03

3. Research Progress on Antiviral Activity of Heparin;Current Medicinal Chemistry;2024-01

4. Heparin-Induced Allosteric Changes in SARS-CoV-2 Spike Protein Facilitate ACE2 Binding and Viral Entry;Nano Letters;2023-12-06

5. Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trials;Thrombosis Research;2023-10